Related Experiment Videos
Gonadal function and immunosuppressive therapy after renal transplantation
V Tondolo1, F Citterio, N Panocchia
1Division of Organ Transplantation, Department of Surgery, Catholic University of Sacred Heart, Rome, Italy. vincenzo.tondolo@rm.unicatt.it
Transplantation Proceedings
|May 28, 2005
Summary
Sirolimus-based immunosuppression may negatively impact male hormone levels after kidney transplantation. Lower testosterone was observed in patients receiving sirolimus, suggesting potential impairment of gonadal function recovery.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Background:
- End-stage renal disease (ESRD) often disrupts hypothalamic-pituitary-gonadal (HPG) function.
- Immunosuppressive drugs used post-renal transplantation can affect the recovery of gonadal hormone levels.
Purpose of the Study:
- To investigate the hormonal status of male renal transplant recipients on different immunosuppressive regimens.
- To evaluate the impact of calcineurin inhibitors (CI) and sirolimus (SRL) on testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels.
Main Methods:
- Hormonal levels (testosterone, LH, FSH) were measured in 59 male renal transplant recipients with stable graft function.
- Patients were categorized into three groups based on immunosuppression: CI (n=15), SRL (n=15), and SRL + CI (n=29).
- Serum creatinine levels were <2.5 mg/dL for all participants.
Main Results:
- Testosterone levels were significantly lower in the SRL group compared to the CI group (P < .0197).
- The SRL + CI group showed intermediate testosterone levels.
- While FSH and LH levels were higher in the SRL group, these differences were not statistically significant.
Conclusions:
- Sirolimus may hinder the restoration of normal gonadal function following renal transplantation.
- Further prospective research is necessary to validate these findings and inform clinical practice regarding potential side effects.